From strategic assessment to full transaction execution

​

Is your company deal-ready?

​

For life-science companies facing a difficult funding and dealmaking environment, the question is not simply whether an asset has potential. The more important question is whether it is genuinely ready to attract a partner, licensee, investor or acquirer.

​

Based on 30+ years of dealmaking in the biopharma industry and very deep analytics using our SAGEIQ platform, Sage can rapidly assess whether a strategic transaction is credible now, identify the most relevant counterparties and define the most effective path from readiness to execution.

​

Sage Healthcare’s Deal Readiness Service helps life-science companies determine whether a licensing, partnering, M&A or strategic financing transaction is achievable — and what must be done to improve the probability of success.

​

For a detailed information document on this process, please click here!

​

The process begins with a focused, fixed-fee Deal Readiness Review, providing management and boards with a clear assessment of partnerability, strategic positioning, valuation metrics, transaction options, target counterparties and key gaps.

​

Where the opportunity is ready, Sage can then transition directly into a full strategic transaction mandate, leading global outreach, partner engagement, diligence, negotiation and transaction completion.

​

Please contact us to set up a call to discuss how we operate this service, timelines and costs!

​​